Sage Therapeutics (FRA:SG7) Total Liabilities : €56.86 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sage Therapeutics Total Liabilities?

Sage Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €56.86 Mil.

Sage Therapeutics's quarterly Total Liabilities declined from Sep. 2023 (€124.63 Mil) to Dec. 2023 (€75.88 Mil) and declined from Dec. 2023 (€75.88 Mil) to Mar. 2024 (€56.86 Mil).

Sage Therapeutics's annual Total Liabilities increased from Dec. 2021 (€85.19 Mil) to Dec. 2022 (€98.03 Mil) but then declined from Dec. 2022 (€98.03 Mil) to Dec. 2023 (€75.88 Mil).

Sage Therapeutics Total Liabilities Historical Data

The historical data trend for Sage Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sage Therapeutics Total Liabilities Chart

Sage Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

125.55

71.44

85.19

98.03

75.88

Sage Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															81.78	90.37	124.63	75.88	56.86

Sage Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sage Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	75.879	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	75.88

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	809.048	-	733.169
	=	75.88

Sage Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	56.855	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	56.86

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	706.192	-	649.337
	=	56.86

Sage Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sage Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sage Therapeutics (FRA:SG7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sage Therapeutics Inc (FRA:SG7) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SAGE:USA SG7:Germany

Address

215 First Street, Cambridge, MA, USA, 02142

Website

https://www.sagerx.com

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.

Sage Therapeutics (FRA:SG7) Headlines

No Headlines